Evaluation of Continuous Subcutaneous Insulin Infusion (CSII) as an Alternative Therapy for Type 1 Diabetes in Paediatric Patients: A Focus on HbA1c Levels.
Keywords:
CSII; type I diabetes; HbAC1; Accu-Chek Combo.Abstract
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder commonly diagnosed in children or teens. This leads to a complete absence of insulin production due to the immune system's targeted destruction of the pancreatic beta cells responsible for insulin synthesis. Effective management of type 1 diabetes necessitates the maintenance of optimal glycemic control to mitigate the risk of acute complications such as hypoglycemia and hyperglycemia, as well as long-term consequences including macrovascular (e.g., cardiovascular disease) and microvascular (e.g., retinopathy and nephropathy) damage. Hemoglobin A1c (HbA1c) serves as the primary biomarker for assessing average blood glucose levels over the past two to three months, hence monitoring long-term glycemic control. This study examines the impact of continuous subcutaneous insulin infusion (CSII) on glycemic control in diabetes care by comparing patient data from before and after the procedure's implementation. Furthermore, to ascertain whether the use of Continuous Subcutaneous Insulin Infusion (CSII) as opposed to Multiple Daily Injections (MDI) diminishes the incidence of severe hypoglycemic episodes in pediatric patients with type 1 diabetes. Samples from fifteen individuals were analyzed, and blood glucose levels were recorded both during and after the transition to Continuous Subcutaneous Insulin Infusion (CSII) and standard insulin therapy. The average glucose levels and variances were analyzed using statistical methods, including Pearson correlation and t-tests. Following the transition to Continuous Subcutaneous Insulin Infusion (CSII), the outcomes demonstrated a significant enhancement in glycemic regulation, characterized by reduced mean glucose levels and diminished variability. These findings suggest that CSII provides.
References
American Diabetes Association. (2021). Glycemic Objectives: Guidelines for Medical Management in Diabetes. Diabetes Care, 44(Suppl 1), S73-S84.
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018). Diabetes mellitus type 1. Lancet, 391(10138), 2449-2462.
Laffel, L., Cheng, J., Cooper, J., et al. (2015). Determinants of glycemic regulation in children, adolescents, and adults with type 1 diabetes. Diabetes Care, Volume 38, Issue 8, Pages 1355-1362.
Danne, T., Kordonouri, O., & Hovorka, R. (2017). Automated pancreatic systems for individuals with type 1 diabetes. Diabetologia, Volume 60, Issue 7, Pages 1323-1332.
Foster, N. C., Beck, R. W., Miller, K. M., et al. (2018). Management and results of type 1 diabetes from the T1D Exchange between 2016-2018. Diabetes Technology & Therapeutics, Volume 21, Issue 2, Pages 66-72.
Pickup, J. C., & Sutton, A. J. (2008). Severe hypoglycemia and glycemic regulation in type 1 diabetes: a meta-analysis of several daily insulin injections versus continuous subcutaneous insulin infusion. Diabetes Medicine, Volume 25, Issue 7, Pages 765-774.
Nuboer, R., Borsboom, G. J., Zoetebier, L., et al. (2018). Continuous subcutaneous insulin infusion and the occurrence of severe hypoglycemia in pediatric patients. Journal of Pediatric Endocrinology and Metabolism, 31(5), 539-544.
Pickup, J.C., Mattock, M.B., Kerry, S., & Williams, G. (2002). Glycaemic management using continuous subcutaneous insulin infusion versus intense insulin injections in individuals with type 1 diabetes: a meta-analysis of randomized controlled trials. BMJ, 324(7339), 705.
Misso, M.L., Egberts, K.J., Page, M., O’Connor, D., & Shaw, J. (2010). Continuous subcutaneous insulin infusion (CSII) compared to repeated insulin injections for diabetes management.
